Chronic myeloid leukemia--advances in biology and new approaches to treatment.
about
Imatinib for treating newly diagnosed chronic myeloid leukemia patientsImatinib for treating patients with chronic myelogeneous leukemiaBcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylationAllosteric inhibition of the nonMyristoylated c-Abl tyrosine kinase by phosphopeptides derived from Abi1/Hssh3bp1Molecular and structural characterization of the SH3 domain of AHI-1 in regulation of cellular resistance of BCR-ABL(+) chronic myeloid leukemia cells to tyrosine kinase inhibitorsEGFR targeted therapy in non-small cell lung cancer: potential role of cetuximabDelineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint ApproachTwo different point mutations in ABL gene ATP-binding domain conferring primary imatinib resistance in a chronic myeloid leukemia (CML) patient: A case reportMicroRNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemiaSomatic DNA mutation analysis in targeted therapy of solid tumoursHsp90 Inhibitors for the Treatment of Chronic Myeloid LeukemiaRole of calcium-dependent protein kinases in chronic myeloid leukemia: combined effects of PKC and BCR-ABL signaling on cellular alterations during leukemia developmentFitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemiaSensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib eraAHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cellsA polymethoxyflavone from Laggera pterodonta induces apoptosis in imatinib-resistant K562R cells via activation of the intrinsic apoptosis pathwayDifferences in structural elements of Bcr-Abl oncoprotein isoforms in Chronic Myelogenous Leukemia.AHI-1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders.Open-access synthetic spike-in mRNA-seq data for cancer gene fusions.Promiscuity and the conformational rearrangement of drug-like molecules: insight from the protein data bank.IgH gene rearrangements as plasma biomarkers in Non- Hodgkin's lymphoma patients.EVI1 activation in blast crisis CML due to juxtaposition to the rare 17q22 partner region as part of a 4-way variant translocation t(9;22).Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intoleranceResponse to imatinib mesylate in patients with hypereosinophilic syndrome.A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate.Changes in cell adhesivity and cytoskeleton-related proteins during imatinib-induced apoptosis of leukemic JURL-MK1 cells.Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinibEnhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer.Drug resistance in cancer: principles of emergence and prevention.Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell linesExpression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy.Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.An automated analysis of highly complex flow cytometry-based proteomic data.Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based reviewmiR-153 sensitized the K562 cells to As2O3-induced apoptosis.Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylateVisualisation of variable binding pockets on protein surfaces by probabilistic analysis of related structure sets.A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas
P2860
Q24186877-468E039F-6952-4C49-93A9-E72D2C4EC660Q24241730-AD119161-31F5-4FB8-BF45-7FC887950324Q24298234-70C76C47-4761-414F-8307-8B937022663AQ24321968-13DA46F4-60C1-4499-A551-630E3E1637A8Q24336197-85F57148-06C7-45CE-B4BA-3478B33994DBQ24652337-E958FB1A-3D79-4A65-A3A8-02B4A66D8D5AQ24672143-8681B903-AD19-4944-BB30-2D8A71CD4F92Q24800045-1300D38A-9E23-412C-9975-B5EF8AF186B2Q26766288-8086A94B-D06C-458D-94B7-E6E52617A204Q26770324-96AEDD87-4822-48AE-8202-4C9C87475B84Q26771790-84444322-C9E8-4268-8485-A21A1DFC7357Q26861674-69837D9A-AE6C-41A9-A014-E3F9A9D07CFFQ28478165-919CDDBD-C37F-4208-950A-A8679194F987Q28486093-1F4E9D9B-ACE7-4D62-A4D4-9B1D24EC3BE9Q28586026-2EBF90DA-2ED0-41A1-BE7D-89BD31A8B00DQ28649477-F4930D41-8E34-4BF7-ADC9-CDDFBC847F0EQ30009436-E23132A7-708D-49EF-88BA-C18410B0CA01Q30010179-DE3ECD5D-81AF-45BB-85F0-578665CB0319Q30487334-A3AF5984-221F-4759-AD64-127B0E33AAE8Q30876537-1DBCD69C-0BB9-4FE6-9EB7-37E4A7F04C3FQ31002231-EF18614F-3D07-4281-9939-0B412D8B01A3Q33350395-FB41A6AB-5B13-470D-90A7-404B3EB9F4BCQ33388870-96B6F993-BAA4-451E-8886-676394313BF9Q33402403-F15B3997-6C50-43D2-A398-4FBCDD3F3A10Q33551475-6127B856-284C-40B9-BC0E-30D62183DECDQ33689672-3A7DBA32-3AC9-45B9-BF1C-90A66360EE32Q33707394-7BB973CC-17DF-4911-8385-7D7E2D8DA524Q33727026-6DEA0C74-01FD-4303-883F-3412907AB9BFQ33892278-F0EA0103-665A-4F0D-9F16-A22AF5D21EEFQ33914049-B15FD70B-B616-4B51-8D1C-5215B9EC096FQ33967180-7D1950E2-E5D3-47DB-94B2-B9EED65E8DF1Q33988398-5C710B33-330C-467D-8269-49AD3708DA2DQ34046343-676994C2-076E-405B-B7AC-D6594F683FDBQ34081881-4CED54E9-7E32-42EF-8542-7F4628DF344AQ34116091-71CD6DD2-A987-4312-8FCA-ADFC5CDE9E15Q34130343-73064E7B-48A6-4247-A15B-521010819145Q34160845-5E07F345-43B7-40B1-854B-0D64E530E7F6Q34184723-E4E52C1F-43D9-4F33-B0CE-7E4BBE7F2458Q34195283-0723F145-AA57-4CE0-92B3-BD28476181B8Q34231554-D885BEDA-E4AE-4406-835D-9731FBC382FA
P2860
Chronic myeloid leukemia--advances in biology and new approaches to treatment.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Chronic myeloid leukemia--advances in biology and new approaches to treatment.
@ast
Chronic myeloid leukemia--advances in biology and new approaches to treatment.
@en
Chronic myeloid leukemia--advances in biology and new approaches to treatment.
@nl
type
label
Chronic myeloid leukemia--advances in biology and new approaches to treatment.
@ast
Chronic myeloid leukemia--advances in biology and new approaches to treatment.
@en
Chronic myeloid leukemia--advances in biology and new approaches to treatment.
@nl
prefLabel
Chronic myeloid leukemia--advances in biology and new approaches to treatment.
@ast
Chronic myeloid leukemia--advances in biology and new approaches to treatment.
@en
Chronic myeloid leukemia--advances in biology and new approaches to treatment.
@nl
P356
P1476
Chronic myeloid leukemia--advances in biology and new approaches to treatment.
@en
P2093
John M Goldman
Junia V Melo
P304
P356
10.1056/NEJMRA020777
P407
P577
2003-10-01T00:00:00Z